4//SEC Filing
Medve Robert 4
Accession 0001181431-13-007977
CIK 0000906709other
Filed
Feb 7, 7:00 PM ET
Accepted
Feb 8, 4:14 PM ET
Size
8.3 KB
Accession
0001181431-13-007977
Insider Transaction Report
Form 4
Medve Robert
Chief Medical Officer
Transactions
- Award
Stock Option
2013-02-06+50,000→ 50,000 totalExercise: $8.80Exp: 2021-02-05→ Common Stock (50,000 underlying) - Award
Stock Option
2013-02-06+50,000→ 50,000 totalExercise: $8.80Exp: 2021-02-05→ Common Stock (50,000 underlying)
Footnotes (2)
- [F1]This option was granted on February 6, 2013 and vests in monthly installments over the four-year period following the grant date.
- [F2]This stock option is subject to both time-based vesting and performance-based vesting conditions, both of which must be met before the shares subject to the option become vested and exerciseable. The time-based vesting is on a monthly pro-rata basis over a period of four (4) years from the grant date (February 6, 2013). The performance-based vesting condition will be met only if Nektar (or a licensee) files a new drug registration with the FDA or the European Medicines Agency for a significant drug candidate program including, without limitation, the following: (1) naloxegol (an oral peripherally-acting opioid antagonist); (2) etirinotecan pegol (a topoisomerase I inhibitor); (3) NKTR-061/Amikacin Inhale (a drug-device combination for an inhaled solution of amikacin); or (4) BAX-855 (a longer-acting (PEGylated) form of a full-length recombinant factor VIII (rFVIII) protein).
Documents
Issuer
NEKTAR THERAPEUTICS
CIK 0000906709
Entity typeother
Related Parties
1- filerCIK 0001546938
Filing Metadata
- Form type
- 4
- Filed
- Feb 7, 7:00 PM ET
- Accepted
- Feb 8, 4:14 PM ET
- Size
- 8.3 KB